Works about DOLUTEGRAVIR
Results: 207
First Reported Case of Integrase Strand Transfer Inhibitor Resistance in Suriname: Unusual Drug Resistance Mutations Following Exposure to Dolutegravir.
- Published in:
- Viruses (1999-4915), 2025, v. 17, n. 2, p. 245, doi. 10.3390/v17020245
- By:
- Publication type:
- Article
Study of Dolutegravir Degradation and Spectroscopic Identification of Products by LCMS, <sup>1</sup>H and <sup>13</sup>C NMR Techniques.
- Published in:
- Pharmaceutical Chemistry Journal, 2019, v. 53, n. 4, p. 368, doi. 10.1007/s11094-019-02007-x
- By:
- Publication type:
- Article
RHAMNETIN IS A BETTER INHIBITOR OF SARS-COV-2 2'-O-METHYLTRANSFERASE THAN DOLUTEGRAVIR: A COMPUTATIONAL PREDICTION.
- Published in:
- African Journal of Infectious Diseases, 2022, v. 16, n. 2, p. 80, doi. 10.21010/ajid.v16i2.9
- By:
- Publication type:
- Article
Nicotine, THC, and Dolutegravir Modulate E-Cigarette-Induced Changes in Addiction- and Inflammation-Associated Genes in Rat Brains and Astrocytes.
- Published in:
- Brain Sciences (2076-3425), 2023, v. 13, n. 11, p. 1556, doi. 10.3390/brainsci13111556
- By:
- Publication type:
- Article
Optimizing antiretroviral therapy for HIV infection: new tendency.
- Published in:
- MEDISAN, 2022, v. 26, n. 1, p. 1
- By:
- Publication type:
- Article
Time for a Change: Optimizing Drug Data and Informed Choice in Pregnancy.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 3, p. e622, doi. 10.1093/infdis/jiae260
- By:
- Publication type:
- Article
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 7, p. 919, doi. 10.1093/infdis/jiad304
- By:
- Publication type:
- Article
Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 7, p. 907, doi. 10.1093/infdis/jiad292
- By:
- Publication type:
- Article
Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.
- Published in:
- Toxicological Sciences, 2021, v. 184, n. 2, p. 191, doi. 10.1093/toxsci/kfab112
- By:
- Publication type:
- Article
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 24, p. 7759, doi. 10.3390/jcm12247759
- By:
- Publication type:
- Article
Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV).
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 3, p. 1176, doi. 10.3390/jcm12031176
- By:
- Publication type:
- Article
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2024, v. 16, p. 133, doi. 10.2147/HIV.S452130
- By:
- Publication type:
- Article
Effect of Multi-Month Dispensing on Viral Suppression for Newly Enrolled Adolescents and Adults in Northern Nigeria.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2023, v. 15, p. 697, doi. 10.2147/HIV.S432976
- By:
- Publication type:
- Article
Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2023, v. 15, p. 173, doi. 10.2147/HIV.S396420
- By:
- Publication type:
- Article
Virological Outcomes After Switching to Abacavir/Lamivudine/Dolutegravir Combined with Adherence Support in People Living with HIV with Poor Adherence: A Phase IV, Multicentre Randomized Prospective Open Label Study (TriiADD-CTN 286).
- Published in:
- Patient Preference & Adherence, 2022, v. 16, p. 3267, doi. 10.2147/PPA.S379065
- By:
- Publication type:
- Article
Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting.
- Published in:
- Patient Preference & Adherence, 2021, v. 15, p. 1177, doi. 10.2147/PPA.S308571
- By:
- Publication type:
- Article
Dolutegravir induces FOLR1 expression during brain organoid development.
- Published in:
- Frontiers in Molecular Neuroscience, 2024, p. 1, doi. 10.3389/fnmol.2024.1394058
- By:
- Publication type:
- Article
Application of signal processing techniques for the spectroscopic analysis of dolutegravir and lamivudine: a comparative assessment and greenness appraisal.
- Published in:
- BMC Chemistry, 2024, v. 18, n. 1, p. 1, doi. 10.1186/s13065-024-01226-y
- By:
- Publication type:
- Article
Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties.
- Published in:
- BMC Chemistry, 2024, v. 18, p. 1, doi. 10.1186/s13065-024-01205-3
- By:
- Publication type:
- Article
Modifying dolutegravir to PrEPare for long life.
- Published in:
- Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-04114-0
- By:
- Publication type:
- Article
Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus.
- Published in:
- SAGE Open Medical Case Reports, 2022, v. 10, p. 1, doi. 10.1177/2050313X221079444
- By:
- Publication type:
- Article
Nasal Administration of Dolutegravir Loaded Nanoparticles Based Mucoadhesive in situ Gel: Design and in vivo Assessment.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2024, v. 58, n. 2, p. 1, doi. 10.5530/ijper.58.2.41
- By:
- Publication type:
- Article
Chemometrics Assisted Spectrophotometric Method Development and Validation for Simultaneous Estimation of Abacavir, Lamivudine and Dolutegravir in Dosage Form.
- Published in:
- Indian Journal of Pharmaceutical Education & Research, 2023, v. 57, n. 2, p. 570, doi. 10.5530/ijper.57.2.70
- By:
- Publication type:
- Article
Brief psychotic episode in a patient living with HIV and treated with dolutegravir. Much more common tan we thought? A case report and review.
- Published in:
- European Psychiatry, 2020, v. 63, p. S348
- By:
- Publication type:
- Article
METHOD DEVELOPMENT AND VALIDATION FOR THE ANALYSIS OF DOLUTEGRAVIR IN PURE AND DOSAGE FORMS USING ULTRAVIOLET-VISIBLE SPECTROSCOPY.
- Published in:
- Indian Drugs, 2023, v. 60, n. 3, p. 47, doi. 10.53879/id.60.03.13026
- By:
- Publication type:
- Article
DESIGN AND DEVELOPMENT OF DOLUTEGRAVIR SODIUM CO-CRYSTALS LOADED ORODISPERSIBLE TABLET WITH IMPROVED DISSOLUTION BEHAVIOUR.
- Published in:
- Indian Drugs, 2023, v. 60, n. 3, p. 30, doi. 10.53879/id.60.03.13278
- By:
- Publication type:
- Article
NOVEL SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ABACAVIR SULPHATE, LAMIVUDINE AND DOLUTEGRAVIR SODIUM IN DOSAGE FORM.
- Published in:
- Indian Drugs, 2022, v. 59, n. 7, p. 44, doi. 10.53879/id.59.07.12415
- By:
- Publication type:
- Article
STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF LAMIVUDINE AND DOLUTEGRAVIR IN BULK AND TABLET DOSAGE FORM.
- Published in:
- Indian Drugs, 2021, v. 58, n. 12, p. 54, doi. 10.53879/id.58.12.12434
- By:
- Publication type:
- Article
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 11, p. 1, doi. 10.1093/ofid/ofae618
- By:
- Publication type:
- Article
Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 8, p. 1, doi. 10.1093/ofid/ofae446
- By:
- Publication type:
- Article
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae365
- By:
- Publication type:
- Article
Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae321
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 5, p. 1, doi. 10.1093/ofid/ofae227
- By:
- Publication type:
- Article
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 5, p. 1, doi. 10.1093/ofid/ofae198
- By:
- Publication type:
- Article
Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 5, p. 1, doi. 10.1093/ofid/ofae139
- By:
- Publication type:
- Article
Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 4, p. 1, doi. 10.1093/ofid/ofae160
- By:
- Publication type:
- Article
Clinical Relevance of Human Immunodeficiency Virus Low-level Viremia in the Dolutegravir era: Data From the Viral Load Cohort North-East Lesotho (VICONEL).
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 2, p. 1, doi. 10.1093/ofid/ofae013
- By:
- Publication type:
- Article
Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 12, p. 1, doi. 10.1093/ofid/ofad583
- By:
- Publication type:
- Article
Preswitch Regimens Influence the Rate of Weight Gain After Switch to Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir (TLD): Study From an East African Cohort.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 12, p. 1, doi. 10.1093/ofid/ofad581
- By:
- Publication type:
- Article
Evaluation of Dolutegravir- and Bictegravir-Based Antiretroviral Regimen Utilization in Patients who Cannot Take Medications by Mouth.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad542
- By:
- Publication type:
- Article
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad526
- By:
- Publication type:
- Article
Strengthening the Evidence: Similar Rates of Neural Tube Defects Among Deliveries Regardless of Maternal HIV Status and Dolutegravir Exposure in Hospital Birth Surveillance in Eswatini.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 9, p. 1, doi. 10.1093/ofid/ofad441
- By:
- Publication type:
- Article
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad359
- By:
- Publication type:
- Article
Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad361
- By:
- Publication type:
- Article
Transitioning to Dolutegravir in a Programmatic Setting: Virological Outcomes and Associated Factors Among Treatment-Naive Patients With HIV-1 in the Kilombero and Ulanga Antiretroviral Cohort in Rural Tanzania.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad321
- By:
- Publication type:
- Article
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 11, p. 1, doi. 10.1093/ofid/ofac610
- By:
- Publication type:
- Article